DUBLIN – Cytos Biotechnology AG out-licensed all oncology applications of its immuno-stimulatory therapeutic vaccine CYT003 and its underlying phage Qbeta-based virus-like particle (VLP) technology to start-up cancer immunotherapy firm Checkmate Pharmaceuticals Inc., in a deal worth up to $90 million in milestones plus double-digit royalties on eventual product sales. Read More
Venetoclax, a small molecule designed to selectively bind and inhibit the B-cell lymphoma 2 (BCL-2) protein, was found worthy in a pivotal phase II study in previously treated patients with chronic lymphocytic leukemia (CLL) who harbor the 17p deletion, and partners Genentech Inc. and Abbvie Inc. said they'll move directly to filings with the FDA and EMA, expected by year-end. Read More
HONG KONG – An unexpected and large drop this week in the reference rate for the value of the Chinese renminbi (RMB) underscored the pressures that companies are facing in a market that remains key to both business and global economic growth. Read More
LONDON – An analysis of journal papers published by participants in Europe's Innovative Medicines Initiative (IMI) shows the €3.3 billion (US$3.6 billion) public/private partnership is now turning out high volumes of high-quality research. Read More
Harvard Apparatus Regenerative Technology Inc. (HART) is teaming up with the Connecticut Children's Medical Center to co-develop a process for repairing or replacing the esophagus to treat life-threatening pediatric conditions such as esophageal atresia. Read More
Southern Research in Birmingham, Ala., won a grant from the National Institute on Drug Abuse to develop opioid drugs for the treatment of chronic pain. Read More
Exelixis Inc., of South San Francisco, reported net product revenue of $8 million from sales of Cometriq (cabozantinib) in the second quarter. Read More
Dermira Inc., of Menlo Park, Calif., said it closed its follow-on offering of about 5.2 million shares, including 675,000 shares to cover the full overallotment option, at a price of $21.50 per share. Read More
Regenerx Biopharmaceuticals Inc., of Rockville, Md., said a paper published in Investigative Ophthalmology and Visual Science describes Thymosin beta 4's (TB4) effects on dry eye syndrome and its potential value for the treatment of other ophthalmic disorders. Read More
